Posted by Michael Wonder on 11 Jan 2022
CARsgen announces CT041 CAR T-cell product candidate granted RMAT designation by the FDA
10 January 2022 - CARsgen Therapeutics today announced that the US FDA granted regenerative medicine advanced therapy designation to CT041 for the treatment of patients who have advanced gastric or gastro-esophageal junction adenocarcinoma with Claudin18.2 positive tumour.
CT041 is the first CAR T-cell product candidate against solid tumour with regenerative medicine advanced therapy designation, according to public resources.
